Evotec Soars 15.9% on Strong Q4 Results, Strategic Plan

On April 18, 2025, Evotec's stock surged by 15.9% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Evotec SE has unveiled a new strategic plan for the future, focusing on drug discovery and sustainable growth. The company's strong Q4 2024 results have bolstered this new strategy, which includes a projected revenue range of €840-880 million for 2025, reflecting a growth rate of 5-10%. Additionally, Evotec anticipates an adjusted Group EBITDA of €30 million, indicating a positive outlook for the company's financial performance.

Looking ahead, Evotec SE expects group revenues to grow by 5-10% in 2025, with a compound annual growth rate of 8-12% projected from 2024 to 2028. This strategic plan aims to refocus on core strengths and define a clear roadmap to sustainable profitable growth, which has been well-received by the market.